多西紫杉醇联合卡培他滨治疗蒽环类耐药的晚期乳腺癌  

Docetaxel plus Capecitabine Combination Therapy for Patients with Anthracycline-resistant Metastatic Breast Cancer

作　　者：柴文英[1] 马芸[1] 李萍[1] 钱锦贤[1] 蒋爱梅[1] 

机构地区：[1]昆明医学院第一附属医院乳腺外科,昆明650032

出　　处：《肿瘤预防与治疗》2011年第4期164-166,共3页Journal of Cancer Control And Treatment

摘　　要：目的:观察多西紫杉醇联合卡培他滨(DC)治疗蒽环类耐药晚期乳腺癌的疗效和安全性。方法:31例经病理证实的蒽环类耐药的转移性乳腺癌患者,采用多西紫杉醇联合卡培他滨化疗。剂量为多西紫杉醇75mg/m^2,静滴,d1;希罗达2 500mg/m^2,口服,d1～d14,21天为1个周期,化疗至疾病进展或不良反应无法耐受。根据WHO制定的实体瘤客观疗效评价标准和抗癌药物毒性分级标准评价疗效和不良反应。结果:31例患者共完成118个周期化疗,每例患者化疗2个～8个周期,中位周期数4个。31例患者中,完全缓解1例(3.2%),部分缓解16例(51.6%),稳定10例(32.3%),进展4例(12.9%),总有效率为54.8%。中位肿瘤进展时间6.3个月,中位生存期13个月,1年生存率为58.8%。主要不良反应为骨髓抑制、胃肠道反应和手足综合征,患者均可耐受。结论:多西紫杉醇联合卡培他滨治疗蒽环类耐药晚期乳腺癌的疗效较好,不良反应可以耐受,是治疗蒽环类耐药晚期乳腺癌的有效方案。Objective： To evaluate the efficacy and toxicity of docetaxel plus capecitabine in the treatment of anthracycline-resistant metastatic breast cancer. Methods： Thirty-one patients with anthracycline-resistant metastatic breast cancer were treated with chemotherapy combined with docetaxel and capecitabine. Docetaxel （75mg/m2 ） was given intravenously on dl and capecitabine （2 500mg/m2 ）was taken orally on dl to d14, every 21 days as one cycle. Results： A total of 118 cycles of the regimen were administered in the 31 cases with a median of 4 cycles（ range 2 -8 cycles for each patient）. The overall response rate was 54.8%. Among the 31 patients, one got complete response（CR） , 16 partial response（PR） , 10 stable disease（SD） and 4 progressive disease（PD）. The median time of progression （TIP） was 6.3 months. The median survival time was 13 months. The one-year survival rate was 58.8%. The major toxicity and adverse effects were myelosuppression, gastrointestinal reaction and hand-food syndrome. Conclusion： Docetaxel plus capecitabine combination therapy is effective and well-tolerated for anthracycline-resistant metastatic breast cancer.

关 键 词：多西紫杉醇 卡培他滨 乳腺癌 联合化疗 

分 类 号：R737.9[医药卫生—肿瘤]